Company news

COSCIENS Biopharma Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aeterna Zentaris Presents Encouraging Preclinical Data for Disorazol Z (AEZS-137) at AACR-NCI-EORTC Conference

November 16, 2011

Aeterna Zentaris Reports Third Quarter 2011 Financial and Operating Results

November 10, 2011

Aeterna Zentaris to Report Third Quarter 2011 Financial and Operating Results on November 10, 2011

November 3, 2011

Aeterna Zentaris to Present at Upcoming Major Cancer Conferences

November 1, 2011

Aeterna Zentaris: FDA Grants IND to Investigator at University of Miami School of Medicine for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer

October 25, 2011

Phase 1/2 Clinical Trial Results of Perifosine Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology

October 13, 2011

Aeterna Zentaris: Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of Perifosine Plus Capecitabine in Patients with Metastatic Colorectal Cancer

October 5, 2011

Aeterna Zentaris Announces Interim Data for its Phase 1/2 Trial with AEZS-108 in Prostate Cancer at ESMO Congress - AEZS-108 well tolerated at all dose levels / Early evidence of anti-tumor activity

September 26, 2011

Aeterna Zentaris to Present at Upcoming 6th Annual JMP Securities Healthcare Conference in New York

September 21, 2011

Aeterna Zentaris Presents Positive Final Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ESGO Meeting in Milan, Italy

September 14, 2011

Aeterna Zentaris to Present at Two Upcoming Investment Conferences in the United States

September 1, 2011

Aeterna Zentaris Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of Perifosine for the Treatment of Refractory Advanced Colorectal Cancer

August 31, 2011

Aeterna Zentaris Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency

August 30, 2011

Aeterna Zentaris to Present Poster on Novel Oral Anticancer Erk Inhibitors at Upcoming American Chemical Society's National Meeting

August 23, 2011

Aeterna Zentaris Reports Second Quarter 2011 Financial and Operating Results

August 10, 2011

Aeterna Zentaris to Announce Second Quarter 2011 Financial and Operating Results on August 10, 2011

August 3, 2011

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference in Boston

August 2, 2011

Aeterna Zentaris Announces Completion of Patient Recruitment for Phase 3 Trial with Perifosine in Refractory Advanced Colorectal Cancer

July 27, 2011

Aeterna Zentaris Completes Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency

July 26, 2011

Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120

July 20, 2011

Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming European Society of Gynaecological Oncology Meeting

July 18, 2011

Aeterna Zentaris Granted Patent for Perifosine by European Patent Office

July 12, 2011

Aeterna Zentaris Announces Poster Presentation of Phase 1/2 Results for AEZS-108 in Prostate Cancer at Upcoming European Society of Medical Oncology Congress

July 7, 2011

Aeterna Zentaris to Present at Upcoming BioFinance 2011 Conference in Toronto

May 25, 2011

Aeterna Zentaris Reports First Quarter 2011 Financial and Operating Results

May 18, 2011

Aeterna Zentaris to Announce First Quarter 2011 Financial and Operating Results and Hold Annual Shareholder Meeting on May 18, 2011

May 11, 2011

Aeterna Zentaris to Present at Upcoming 10th Annual JMP Securities Research Conference in San Francisco

May 4, 2011

Aeterna Zentaris Announces Results on AEZS-131, a Highly Selective Erk 1/2 Inhibitor Anticancer Compound at American Association for Cancer Research Annual Meeting

April 5, 2011

← Newer news releases

Decks

The 5 newest of 7 decks. Every deck is listed under its year.